24-Feb-2026 6:01 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at
19-Feb-2026 3:01 PM CST - Business Wire Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners
24-Feb-2026 6:01 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at
19-Feb-2026 3:01 PM CST - Business Wire Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners
